药物对比
Linagliptin vs Sotagliflozin
Linagliptin 与 Sotagliflozin：DPP-4与双重SGLT1/SGLT2抑制剂治疗2型糖尿病和心力衰竭。比较心血管获益、疗效、副作用及哪种更好。
此页面暂无可用的对比维度。
临床背景
This comparison arises when selecting between a DPP-4 inhibitor and dual SGLT inhibitor for type 2 diabetes, especially with heart failure or CV risk.
结论
Sotagliflozin often provides superior heart failure and CV benefits over Linagliptin, but the latter may be preferred to avoid SGLT-related risks.
全部药物对比